Journal
CLINICAL IMMUNOLOGY
Volume 123, Issue 1, Pages 66-73Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.clim.2006.12.006
Keywords
regulatory cells; rituximab; T cell; B cell; thymus; autoimmunity; lupus; nephritis; CD40L; TGF-beta; FOXP3
Categories
Ask authors/readers for more resources
B cell depletion may affect T cell activation and costimulation status in rituximab-treated patients with SLE. We examined whether rituximab administration in patients with active lupus nephritis is related to changes in mRNA expression of genes that define regulatory T cells (Tregs) in peripheral blood lymphocytes, measured by real-time PCR. At the early phase of B cell depletion mRNA levels of CD25, CTLA-4, GITR and the bona fide Treg functional. marker FOXP3 increased significantly in all 7 patients examined. In contrast, mRNA levels of the costimutatory/ activation T cell molecule CD40L were profoundly reduced, white mRNA levels of TGF-beta, a cytokine contributing to Treg induction, increased significantly in all. During follow-up, increased FOXP3 mRNA persisted in those patients in clinical remission, white in those patients with active disease subsequent decreases were noted. Further studies should examine whether modulation of Tregs by therapeutic B cell depletion contributes and/or predicts lupus disease remission. (c) 2006 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available